Sanofi has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.
Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 best-in-class manufacturing sites and four research and innovation centers.
With a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world’s third-largest company in the over the counter and vitamins, minerals, and supplements market, serving more than half a billion consumers worldwide.
Opella’s journey to independence aligns with Sanofi’s strategy to focus on innovative medicines and vaccines. Opella already operates today as a standalone business unit within Sanofi, with dedicated resources for R&D, production, digital, and with its own sustainability roadmap.
Opella achieved 6.3% sales growth at constant exchange rates in 2023.
